Tetanus/Diphtheria Vaccine In Shortage; CDC Prioritizes Travel Immunizations
Adult tetanus/diphtheria vaccine is in short supply following cessation of manufacturing by Wyeth-Ayerst and retooling of a plant by Aventis.
You may also be interested in...
Wyeth-Ayerst would have to pay the government 18.5% of future net sales from products manufactured at its Marietta, Penn. facility if it fails to meet a timeline for bringing the plant into compliance with current Good Manufacturing Practices under an Oct. 3 consent decree with FDA.
The potential for vaccine manufacturers to exit the business is "very troubling" to FDA, Center for Biologics Evaluation & Research Director Kathryn Zoon, PhD, told the Regulatory Affairs Professionals Society annual meeting in Washington, D.C. Oct. 4.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011